Response to therapy with once-monthly ibandronate 150 mg: Post-hoc analysis of BMD responders from the mobile study

被引：0
|
作者：
Silverman, S. L.
Hochberg, M.
Cole, R. E.
Barr, C. E.
Genant, H. K.
机构：
[1] Osteoporosis Med Ctr, Beverly Hills, CA USA
[2] Univ Maryland, Baltimore, MD 21201 USA
[3] Michigan State Univ, Brooklyn, NY USA
[4] Roche Labs, Nutley, NJ USA
[5] Univ Calif San Francisco, Med Ctr, San Francisco, CA 94143 USA
来源：
OSTEOPOROSIS INTERNATIONAL | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S242 / S242
页数：1
相关论文
共 50 条
  • [1] Response to once-monthly and daily oral ibandronate in the mobile study: 2-year analysis
    不详
    CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S145 - S145
  • [2] Efficacy and Tolerability of Once-Monthly Oral Ibandronate (150 mg) and Once-Weekly Oral Alendronate (70 mg): Additional Results From the Monthly Oral Therapy With Ibandronate for Osteoporosis Intervention (MOTION) Study
    Emkey, Ronald
    Delmas, Pierre D.
    Bolognese, Michael
    Borges, Lindolfo C.
    Cosman, Felicia
    Ragi-Eis, Sergio
    Recknor, Christopher
    Zerbini, Cristiano A.
    Neate, Colin
    Sedarati, Farhad
    Epstein, Solomon
    CLINICAL THERAPEUTICS, 2009, 31 (04) : 751 - 761
  • [3] Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study
    Potkin, Steven G.
    Loze, Jean-Yves
    Forray, Carlos
    Baker, Ross A.
    Sapin, Christophe
    Peters-Strickland, Timothy
    Beillat, Maud
    Nylander, Anna-Greta
    Hertel, Peter
    Schmidt, Simon Nitschky
    Ettrup, Anders
    Eramo, Anna
    Hansen, Karina
    Naber, Dieter
    PLOS ONE, 2017, 12 (08):
  • [4] The MOBILE study long-term extension: Progressive bone density gains with 150mg once-monthly oral ibandronate.
    Miller, P. D.
    Luckey, M.
    Cooper, C.
    Stakkestad, J. A.
    Hughes, C.
    Bolognese, M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S417 - S417
  • [5] Effect sizes of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia: a post-hoc analysis of QUALIFY
    Potkin, S.
    Schmidt, S. Nitschky
    Salzman, P.
    Such, P.
    Ettrup, A.
    Eramo, A.
    Hansen, K.
    Naber, D.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S564 - S565
  • [6] ARIPIPRAZOLE ONCE-MONTHLY FOR THE TREATMENT OF SCHIZOPHRENIA IN OBESE AND NON-OBESE PATIENTS; A POST-HOC ANALYSIS
    De Hert, M.
    Eramo, A.
    Landsberg, W.
    Tsai, L. F.
    Kostic, D.
    Baker, R.
    EUROPEAN PSYCHIATRY, 2014, 29
  • [7] Boniva - Ibandronate 150-mg tablets - Roche/GlaxoSmithKline - First once-monthly therapy approved for treatment and prevention of osteoporosis
    不详
    FORMULARY, 2005, 40 (05) : 144 - 145
  • [8] Once-monthly oral ibandronate (150mg) provides superior efficacy versus daily dosing: 2-year results from mobile
    Felsenberg, D.
    Greenwald, M.
    Need, A.
    Elizondo-Alanis, L-J
    Hughes, C.
    Mairon, N.
    Coutant, K.
    Radominski, S.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S211 - S212
  • [9] The efficacy and safety of aripiprazole once-monthly in obese and non-obese patients with schizophrenia; a post-hoc analysis
    Eramo, A.
    De Hert, M.
    Landsberg, W.
    Tsai, L. -F.
    Baker, R. A.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 69 - 69
  • [10] Influence of baseline patient characteristics on response to once-monthly and daily oral ibandronate therapy: 2-year findings from mobile
    Reginster, J. Y.
    Hawker, G.
    Bolognese, M.
    Coutant, K.
    Hughes, C.
    Sedarati, F.
    Stone, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 426 - 426
12345